← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Thermo Fisher Scientific TMO $249B	1,350	+28	+2%	$86.9B
2	2 Danaher DHR $158B	1,265	+18	+1%	$59.8B
3	3 Novartis NVS $279B	1,028	+41	+4%	$22.5B
4	4 Illumina ILMN $41B	797	+50	+7%	$48.6B
5	5 Agilent Technologies A $49.1B	671	+2	+0.3%	$19.2B
6	6 Regeneron Pharmaceuticals REGN $80.1B	644	+20	+3%	$29.8B
7	7 Revvity RVTY $17B	399	+24	+6%	$10.3B
8	8 Charles River Laboratories CRL $14.4B	366	+18	+5%	$6.27B
9	9 Sarepta Therapeutics SRPT $1.78B	345	+27	+8%	$9.89B
10	10 Ionis Pharmaceuticals IONS $7.1B	322	+14	+5%	$6.11B
11	11 Alnylam Pharmaceuticals ALNY $30B	305	-5	-2%	$7.94B
12	12 DELISTED bluebird bio BLUE	288	-19	-6%	$8.48B
13	13 Myriad Genetics MYGN $397M	284	+26	+10%	$3.48B
14	14 DELISTED CATALENT, INC. CTLT	277	+15	+6%	$6.49B
15	15 Qiagen QGEN $9.41B	246	+14	+6%	$5.43B
16	16 Azenta AZTA $1.63B	243	+14	+6%	$2.44B
17	17 Bruker BRKR $8.47B	220	-7	-3%	$3.47B
18	18 DELISTED SANGAMO THERAPEUTICS INC SGMO	217	+7	+3%	$1.1B
19	19 Regenxbio RGNX $454M	203	+26	+15%	$2.16B
20	20 Editas Medicine EDIT $349M	199	-15	-7%	$1.06B
21	21 PTC Therapeutics PTCT $4.98B	180	+14	+8%	$2.2B
22	22 CRISPR Therapeutics CRSP $4.86B	179	+5	+3%	$1.01B
23	23 Ultragenyx Pharmaceutical RARE $1.47B	177	+19	+12%	$3.8B
24	24 Precigen PGEN $2.64B	170	+4	+2%	$2.08B
25	25 Intellia Therapeutics NTLA $1.6B	157	+1	+0.6%	$833M